|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2009-12-17
|
|
pubmed:abstractText |
Recombinant monoclonal antibodies have emerged as important tools for cancer therapy. Despite the promise shown by antibody-based therapies, the large molecular size of antibodies limits their ability to efficiently penetrate solid tumors and precludes efficient crossing of the blood-brain-barrier into the central nervous system (CNS). Consequently, poorly vascularized solid tumors and CNS metastases cannot be effectively treated by intravenously-injected antibodies. The inherent tumor-tropic properties of human neural stem cells (NSCs) can potentially be harnessed to overcome these obstacles and significantly improve cancer immunotherapy. Intravenously-delivered NSCs preferentially migrate to primary and metastatic tumor sites within and outside the CNS. Therefore, we hypothesized that NSCs could serve as an ideal cellular delivery platform for targeting antibodies to malignant tumors.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-11406546,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-11406547,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-11951641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-14670128,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-14749494,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-14750129,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-15199112,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-15316127,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-16291774,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-16322262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-16524944,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-17183650,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-17210679,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-17483330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-18369324,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-18403751,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-18936791,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-19008049,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-19074827,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-19127251,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20016813-8095168
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Culture Media, Conditioned,
http://linkedlifedata.com/resource/pubmed/chemical/HER2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1932-6203
|
|
pubmed:author |
pubmed-author:AboodyKaren SKS,
pubmed-author:CheungChia-WeiCW,
pubmed-author:EdmistonMarissaM,
pubmed-author:FrankRichard TRT,
pubmed-author:GlackinCarlotta ACA,
pubmed-author:KassaThewodrosT,
pubmed-author:KendallStephen ESE,
pubmed-author:KimSeung USU,
pubmed-author:MetzMarianne ZMZ,
pubmed-author:NajbauerJosephJ,
pubmed-author:WuAnna MAM,
pubmed-author:YazakiPaul JPJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e8314
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20016813-Animals,
pubmed-meshheading:20016813-Antibodies, Monoclonal,
pubmed-meshheading:20016813-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20016813-Antibody Specificity,
pubmed-meshheading:20016813-Breast Neoplasms,
pubmed-meshheading:20016813-Cell Line, Tumor,
pubmed-meshheading:20016813-Cell Movement,
pubmed-meshheading:20016813-Culture Media, Conditioned,
pubmed-meshheading:20016813-Drug Delivery Systems,
pubmed-meshheading:20016813-Female,
pubmed-meshheading:20016813-Immunoglobulin G,
pubmed-meshheading:20016813-Mice,
pubmed-meshheading:20016813-Mice, Nude,
pubmed-meshheading:20016813-Neurons,
pubmed-meshheading:20016813-Organ Specificity,
pubmed-meshheading:20016813-Receptor, erbB-2,
pubmed-meshheading:20016813-Stem Cells,
pubmed-meshheading:20016813-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.
|
|
pubmed:affiliation |
Division of Hematology, City of Hope National Medical Center and Beckman Research Institute, Duarte, California, USA. rikfrank@gmail.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
